Research

Periodontitis and mortality risk in adults with diabetes

15.11.23

Periodontitis, a chronic inflammatory disease affecting the supporting structures of the teeth, has been linked to various systemic health issues, including cardiovascular disease and diabetes. Given the increasing prevalence of both diabetes and periodontal disease, understanding their interplay is crucial for public health.

Periodontal disease and COPD: UK Biobank Studies

18.10.23

The study investigates the association between periodontal diseases and chronic obstructive pulmonary disease (COPD), motivated by emerging evidence suggesting a potential link between oral health and respiratory conditions.

Long-term periodontal treatment outcomes in stages III and IV periodontitis patients

19.09.23

The study represents a significant contribution to the understanding of long-term outcomes in periodontal treatment, specifically for patients diagnosed with stages III and IV periodontitis. With the ultimate goal of preserving natural teeth for life, the research addresses the critical need for comprehensive data on tooth loss and treatment efficacy over extended periods.

The biochemical link between hyperglycaemia and periodontal inflamm-ageing

03.09.23

Diabetes mellitus (DM) is a significant risk factor for periodontal disease, characterised by hyperglycaemia, chronic inflammation, and compromised immune defence. Poorly controlled blood glucose levels increase the prevalence and severity of periodontal disease, impacting the quality of life for affected individuals. Recent research has introduced the concept of ‘inflamm-ageing’- a pro-inflammatory state linked to diabetes that exacerbates tissue damage through macrophage activation.

Serum α-tocopherol acetate improves alveolar bone loss in those with diabetes and periodontitis

19.08.23

• Periodontitis, characterised by inflammatory-driven alveolar bone destruction, is exacerbated by diabetes mellitus (DM), which increases inflammatory and pro-osteoclastogenic (formation of bone-resorbing cells) factors in the periodontium.
• Conventional therapies for those with diabetes and periodontitis are limited, necessitating innovative treatments.
• Gut microbiota plays a critical role in regulating inflammation and metabolism, with positive modulation showing potential in alleviating disease.

Subgingival therapy and glycaemic control in type 2 diabetes

31.05.23

There is a well-established bidirectional relationship between periodontitis and diabetes. Individuals with poorly controlled diabetes are at a higher risk of developing periodontal disease due to the effects of hyperglycaemia on immune function and tissue healing. On the other hand, periodontal disease can exacerbate glycaemic control, leading to increased insulin resistance and worsening metabolic outcomes. The systemic inflammation associated with periodontal disease is believed to contribute to the pathophysiology of diabetes, as inflammatory mediators can interfere with insulin signalling pathways.<

PGC-1α activation enhances silibinin’s therapeutic effects in type 1 diabetic periodontitis

20.03.23

• Diabetic periodontitis (DP) is a term used to describe periodontitis influenced by diabetes.
• Diabetes is thought to exacerbate periodontitis through various pathogenic mechanisms, including mitochondrial dysfunction.

An analysis between periodontal condition and glycaemic status

19.03.23

Periodontal disease, a chronic inflammatory condition affecting the supporting structures of teeth, is prevalent among individuals with diabetes, who are often at a heightened risk due to compromised immune responses and metabolic dysregulation. Conversely, poor glycaemic control has been implicated in the progression of periodontal disease, suggesting a bidirectional relationship that warrants further investigation.

Glycaemic control in the prevention of peri-implant diseases

19.02.23

Peri-implant diseases (PIDs), including peri-implant mucositis and peri-implantitis, are significant complications that can arise following dental implant placement. These conditions are characterised by inflammation of the peri-implant tissues, which can lead to implant failure if not managed effectively.

Acute-phase response in periodontal treatment in type 2 diabetes

22.01.23

Periodontal treatment involves a stepwise framework, including non-surgical sub-gingival instrumentation as the cornerstone for managing periodontitis. This reduces gingival inflammation, probing pocket depth (PPD), and clinical attachment loss (CAL) while improving overall health and quality of life. However, non-surgical treatment can induce an acute-phase systemic inflammatory reaction post-operatively, including increased acute-phase proteins, endothelial dysfunction, elevated body temperature, clotting tendencies, and renal function reduction.

Periodontitis and mortality risk in adults with diabetes

15.11.23

Periodontitis, a chronic inflammatory disease affecting the supporting structures of the teeth, has been linked to various systemic health issues, including cardiovascular disease and diabetes. Given the increasing prevalence of both diabetes and periodontal disease, understanding their interplay is crucial for public health.

Periodontal disease and COPD: UK Biobank Studies

18.10.23

The study investigates the association between periodontal diseases and chronic obstructive pulmonary disease (COPD), motivated by emerging evidence suggesting a potential link between oral health and respiratory conditions.

Long-term periodontal treatment outcomes in stages III and IV periodontitis patients

19.09.23

The study represents a significant contribution to the understanding of long-term outcomes in periodontal treatment, specifically for patients diagnosed with stages III and IV periodontitis. With the ultimate goal of preserving natural teeth for life, the research addresses the critical need for comprehensive data on tooth loss and treatment efficacy over extended periods.

The biochemical link between hyperglycaemia and periodontal inflamm-ageing

03.09.23

Diabetes mellitus (DM) is a significant risk factor for periodontal disease, characterised by hyperglycaemia, chronic inflammation, and compromised immune defence. Poorly controlled blood glucose levels increase the prevalence and severity of periodontal disease, impacting the quality of life for affected individuals. Recent research has introduced the concept of ‘inflamm-ageing’- a pro-inflammatory state linked to diabetes that exacerbates tissue damage through macrophage activation.

Serum α-tocopherol acetate improves alveolar bone loss in those with diabetes and periodontitis

19.08.23

• Periodontitis, characterised by inflammatory-driven alveolar bone destruction, is exacerbated by diabetes mellitus (DM), which increases inflammatory and pro-osteoclastogenic (formation of bone-resorbing cells) factors in the periodontium.
• Conventional therapies for those with diabetes and periodontitis are limited, necessitating innovative treatments.
• Gut microbiota plays a critical role in regulating inflammation and metabolism, with positive modulation showing potential in alleviating disease.

Subgingival therapy and glycaemic control in type 2 diabetes

31.05.23

There is a well-established bidirectional relationship between periodontitis and diabetes. Individuals with poorly controlled diabetes are at a higher risk of developing periodontal disease due to the effects of hyperglycaemia on immune function and tissue healing. On the other hand, periodontal disease can exacerbate glycaemic control, leading to increased insulin resistance and worsening metabolic outcomes. The systemic inflammation associated with periodontal disease is believed to contribute to the pathophysiology of diabetes, as inflammatory mediators can interfere with insulin signalling pathways.<

PGC-1α activation enhances silibinin’s therapeutic effects in type 1 diabetic periodontitis

20.03.23

• Diabetic periodontitis (DP) is a term used to describe periodontitis influenced by diabetes.
• Diabetes is thought to exacerbate periodontitis through various pathogenic mechanisms, including mitochondrial dysfunction.

An analysis between periodontal condition and glycaemic status

19.03.23

Periodontal disease, a chronic inflammatory condition affecting the supporting structures of teeth, is prevalent among individuals with diabetes, who are often at a heightened risk due to compromised immune responses and metabolic dysregulation. Conversely, poor glycaemic control has been implicated in the progression of periodontal disease, suggesting a bidirectional relationship that warrants further investigation.

Glycaemic control in the prevention of peri-implant diseases

19.02.23

Peri-implant diseases (PIDs), including peri-implant mucositis and peri-implantitis, are significant complications that can arise following dental implant placement. These conditions are characterised by inflammation of the peri-implant tissues, which can lead to implant failure if not managed effectively.

Acute-phase response in periodontal treatment in type 2 diabetes

22.01.23

Periodontal treatment involves a stepwise framework, including non-surgical sub-gingival instrumentation as the cornerstone for managing periodontitis. This reduces gingival inflammation, probing pocket depth (PPD), and clinical attachment loss (CAL) while improving overall health and quality of life. However, non-surgical treatment can induce an acute-phase systemic inflammatory reaction post-operatively, including increased acute-phase proteins, endothelial dysfunction, elevated body temperature, clotting tendencies, and renal function reduction.